Avenue Therapeutics Inc. (ATXI)
NASDAQ: ATXI
· Real-Time Price · USD
0.50
-0.04 (-7.41%)
At close: Aug 11, 2025, 11:48 AM
Avenue Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -9.48M | -11.28M | -11.81M | -10.72M | -11.82M | -14.54M | -16.33M | -14.93M | -11.61M | -8.04M | -5.04M | -5.25M | -5.6M | -3.74M | -3.82M | -3.99M | -4.94M |
Interest Income | 159K | 176K | 174K | 132K | 137K | 125K | 119K | 111K | 55K | 20K | 5K | 5K | 6K | 7K | 12K | 20K | 33K |
Pretax Income | -9.2M | -11.7M | -9.52M | -5.92M | -7.24M | -10.49M | -10.58M | -11.76M | -8.34M | -3.6M | -5.04M | -5.25M | -5.59M | -3.73M | -3.81M | -3.97M | -4.91M |
Net Income | -13.66M | -16.15M | -13.96M | -10.36M | -7.18M | -10.38M | -10.44M | -11.63M | -8.23M | -3.55M | -5.04M | -5.25M | -5.59M | -3.73M | -3.81M | -3.97M | -4.91M |
Selling & General & Admin | 4.82M | 4.64M | 4.74M | 5.08M | 4.51M | 4.18M | 6.41M | 5.72M | 5.27M | 5.34M | 2.5M | 2.63M | 2.8M | 2.48M | 2.48M | 2.45M | 2.51M |
Research & Development | 4.66M | 6.64M | 7.06M | 5.64M | 7.31M | 10.36M | 9.92M | 9.21M | 6.33M | 2.7M | 2.54M | 2.63M | 2.8M | 1.25M | 1.35M | 1.54M | 2.43M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 9.48M | 11.28M | 11.81M | 10.72M | 11.82M | 14.54M | 16.33M | 14.93M | 11.61M | 8.04M | 5.04M | 5.25M | 5.6M | 3.74M | 3.82M | 3.99M | 4.94M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | 332K | 1.49M | 1.49M | 1.49M | 1.16M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 9.48M | 11.28M | 11.81M | 10.72M | 11.82M | 14.54M | 16.33M | 14.93M | 11.61M | 8.04M | 5.04M | 5.25M | 5.6M | 3.74M | 3.82M | 3.99M | 4.94M |
Income Tax Expense | -9K | n/a | 9K | 6.93K | 6.93K | -2.07K | -2.07K | -2K | -3K | -7K | -7K | -5K | -4K | n/a | -6K | -6K | -6K |
Shares Outstanding (Basic) | 2.97M | 1.6M | 1.6M | 1.12M | 562.04K | 25.6M | 8.11M | 7.76M | 5.57M | 1.41M | 1.47M | 1.46M | 1.4M | 1.22M | 1.11M | 1.1M | 1.1M |
Shares Outstanding (Diluted) | 2.97M | 1.6M | 1.6M | 1.12M | 562.04K | 25.6M | 8.11M | 103.44K | 5.57M | 1.41M | 1.47M | 1.46M | 1.4M | 1.22M | 1.11M | 1.1M | 1.1M |
EPS (Basic) | -4.43 | -11.53 | -16.05 | -9.26 | -41.57 | -135.43 | -131.88 | -137.19 | -98.86 | -151.04 | -155.36 | -155.7 | -156.15 | -3.3 | -3.45 | -3.59 | -4.45 |
EPS (Diluted) | -4.43 | -11.53 | -16.05 | -9.26 | -41.57 | -135.43 | -131.88 | -137.19 | -98.86 | -151.04 | -155.36 | -155.7 | -156.15 | -3.3 | -3.45 | -3.59 | -4.45 |
EBITDA | -9.25M | -11.05M | -6.76M | -3.16M | -4.33M | -7.05M | -4.18M | -5.36M | -2.1M | 1.47M | -5.04M | -5.25M | -5.6M | -3.74M | -3.82M | -3.99M | -4.94M |
EBIT | -9.25M | -11.7M | -9.52M | -5.92M | -7.24M | -10.16M | -9.09M | -10.26M | -6.85M | -2.44M | -5.04M | -5.25M | -5.6M | -3.74M | -3.82M | -3.99M | -4.94M |
Depreciation & Amortization | -3.71M | n/a | 6.02M | 8.02M | 11.82M | 14.54M | 16.33M | 14.93M | 11.61M | 8.04M | 5.04M | 5.25M | 5.6M | 3.74M | 3.82M | 3.99M | 4.94M |